Does PEMBROLIZUMAB Cause Hypertransaminasaemia? 231 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 231 reports of Hypertransaminasaemia have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.3% of all adverse event reports for PEMBROLIZUMAB.
231
Reports of Hypertransaminasaemia with PEMBROLIZUMAB
0.3%
of all PEMBROLIZUMAB reports
8
Deaths
117
Hospitalizations
How Dangerous Is Hypertransaminasaemia From PEMBROLIZUMAB?
Of the 231 reports, 8 (3.5%) resulted in death, 117 (50.6%) required hospitalization, and 9 (3.9%) were considered life-threatening.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 231 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
RITUXIMAB (168)
Which PEMBROLIZUMAB Alternatives Have Lower Hypertransaminasaemia Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G